Racquel Bracken
General Partner at Venrock
Racquel Bracken
General Partner at Venrock
Palo Alto, California
Overview
Work Experience
General Partner
2016 - Current
Investing broadly in private healthcare companies with an interest in biotech
Venrock is a venture capital firm investing in technology and healthcare companies.
Board Member
2024
Board Member
2021
Discovering and developing novel antibody drug conjugate antibody therapies in oncology
Board Member, Treasurer
2019
Essential Access Health (formerly California Family Health Council) is a non-profit organization that champions and promotes quality sexual and reproductive health care for all. Essential Access Health achieves its mission through an umbrella of services including advanced clinical research, provider training, patient education and consumer awareness, public policy and clinic support initiatives. As the administrator of the nation's largest Title X federal family planning program, we partner with a diverse provider network that collectively serves nearly one million women, men and teens annually at more than 340 health centers in 37 of California's 58 counties.
Essential Access Health is a non-profit organization that champions and promotes quality sexual and reproductive health care for all.
Acting Chief Executive Officer
2022 - 2024
Confluence Therapeutics is pioneering a novel platform of RNA binding protein targeted oligonucleotide therapeutics for therapeutic areas with significant unmet need.
Board Member
2017 - 2023
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Raised $156,700,000.00 from CaaS Capital Management, Venrock, Droia Ventures, Ample Plus Fund, Ally Bridge Group, Lightstone Ventures, Avidity Partners, Acuta Capital Partners, Janus Henderson Investors and Novo Holdings.
CEO and co-founder
2018 - 2020
Microbial cell therapy for diseases with high unmet medical need
Marketing Director
2015 - 2016
Responsible for leading the marketing team for rucaparib, a PARP inhibitor for the treatment of advanced ovarian cancer. Rucaparib received breakthrough therapy designation from the FDA in 2015 and NDA filing is expected mid-2016.
Head of Business Development
2009 - 2016
Responsible for the in-licensing of the current Clovis pipeline, including: global rights to rociletinib (CO-1686) from Avila Therapeutics (now Celgene), rucaparib (CO-338) from Pfizer, and US and Japanese right to lucitanib from EOS.
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments.
Raised $145,000,000.00 from Pfizer Venture Investments, ProQuest Investments, Frazier Healthcare Partners, Domain Associates, Versant Ventures, Aberdare Ventures, New Enterprise Associates and Abingworth.
Associate
2006 - 2009
Analyst
2005 - 2006
Education
AB
2001 - 2005